Tom Graney
Chief Executive Officer, Oxurion

Tom Graney has extensive capital markets and business development experience in biotech as the Chief Financial Officer of several successful public companies. This includes having raised >$500M in capital for highly innovative companies like Oxurion and completing a number of value creating business development transactions. He also has an impressive track record of developing high performing teams and talent everywhere he has worked both in the United States and Europe.

Mr. Graney’s transatlantic experience in creating significant company and shareholder value makes him uniquely qualified to lead Oxurion as its next CEO as it moves its highly differentiated assets through clinical development.

He joined Oxurion as Chief Financial Officer in October 2020, and has over 25 years’ experience in senior finance, strategy, business development and operational roles including most recently as CFO of Generation Bio (NASDAQ: GBIO), and before that CFO of Vertex Pharmaceuticals (NASDAQ: VRTX), and CFO and Head of Corporate Strategy at Ironwood Pharmaceuticals (NASDAQ: IRWD). Earlier in his career he spent 20 years with Johnson and Johnson, including CFO roles at Ethicon, Tibotec and Janssen. Tom also serves on the board of AC Immune (NASDAQ: ACIU).

Mr. Graney has an MBA in finance, marketing and international business from the Leonard N. Stern School of Business at New York University and a BS in accounting from the University of Delaware. He is also a CFA charterholder.